XERVYTEG Trademark

Trademark Overview

On Wednesday, May 28, 2025, a trademark application was filed for XERVYTEG with the United States Patent and Trademark Office. The USPTO has given the XERVYTEG trademark a serial number of 99205147. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, June 20, 2025. This trademark is owned by MAAT PHARMA. The XERVYTEG trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Pharmaceutical and biopharmaceutical products and preparations for medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction, and for treating cancers and diseases, namely, neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases; Pharmaceuticals for treatment, maintaining and restoring human health in the field of disturbed microbial community, and treatment for dysbiosis, cancers, and diseases, including neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases; Biological preparations in the nature of microorganisms used to treat, maintain and restore human health in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, and diseases including neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases

Medical and surgical apparatus and instruments; drug delivery devices, including medical apparatus and instruments for administration of pharmaceutical and biopharmaceutical products and preparations; Drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, in the nature of a kit comprising a prefilled suspension bag and administration tube set
xervyteg

General Information

Serial Number99205147
Word MarkXERVYTEG
Filing DateWednesday, May 28, 2025
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, June 20, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Description of MarkThe mark consists of XERVYTEG in purple and in a stylized format.
Goods and ServicesPharmaceutical and biopharmaceutical products and preparations for medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction, and for treating cancers and diseases, namely, neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases; Pharmaceuticals for treatment, maintaining and restoring human health in the field of disturbed microbial community, and treatment for dysbiosis, cancers, and diseases, including neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases; Biological preparations in the nature of microorganisms used to treat, maintain and restore human health in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, and diseases including neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases
Indication of Colors claimedThe color(s) purple and yellow is/are claimed as a feature of the mark.
Goods and ServicesMedical and surgical apparatus and instruments; drug delivery devices, including medical apparatus and instruments for administration of pharmaceutical and biopharmaceutical products and preparations; Drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, in the nature of a kit comprising a prefilled suspension bag and administration tube set

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 28, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateWednesday, May 28, 2025
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMAAT PHARMA
Party Type10 - Original Applicant
Legal Entity Type33 - NOT AVAILABLE
AddressLyon 69007
FR

Trademark Events

Event DateEvent Description
Wednesday, May 28, 2025NEW APPLICATION ENTERED
Friday, June 6, 2025NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, June 6, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 18, 2025ASSIGNED TO EXAMINER
Friday, June 20, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, June 20, 2025NON-FINAL ACTION E-MAILED
Friday, June 20, 2025NON-FINAL ACTION WRITTEN
Wednesday, May 28, 2025APPLICATION FILING RECEIPT MAILED

Related Keywords

xervyteg diseases gastrointestinal psychiatric neurological cancers treatment infectious autoimmune inflammatory metabolic